news
Combination therapy shows promise for functional HIV cure
The immunomodulator N-803, an Interleukin-15 superagonist, combined with two broadly neutralizing antibodies, significantly reduced viral load in people living with HIV. This sustained reduction happened even without antiretroviral therapy, signaling a potential path toward a functional cure. Researchers presented the findings at the International AIDS Society Congress.
The immunomodulator N-803, an Interleukin-15 superagonist, combined with two broadly neutralizing antibodies, significantly reduced viral load in people living with HIV. This sustained reduction happened even without antiretroviral therapy, signaling a potential path toward a functional cure. Researchers presented the findings at the International AIDS Society Congress.
The architecture take
Okay, so a functional HIV cure is still a big 'if,' but this combo therapy is the closest we’ve seen to a sustained viral load reduction without daily pills. The Interleukin-15 superagonist works by boosting T-cells, those immune system bouncers, while the antibodies neutralize the virus. It's not eradicating HIV, but it’s keeping it low enough that the body can mostly manage it on its own. This is a huge shift from a lifelong drug regimen to something more like long-term remission. For people living with HIV, it means fewer side effects and potentially more normal nervous system regulation without the constant chemical load. The next step is scaling this, obviously, and figuring out who responds best. This isn’t a miracle pill yet, but it’s a big deal for biological independence.